Department of Basic Medical Science, Institute of Respiratory Disease, Neuroscience, and Sense Organs, University of Bari "Aldo Moro", Bari, Italy.
General Direction, Policlinico Hospital, Bari, Italy.
Respir Res. 2021 Jan 15;22(1):16. doi: 10.1186/s12931-021-01613-2.
Some studies investigated epidemiological and clinical features of laboratory-confirmed patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) the virus causing coronavirus disease 2019 (COVID-19), but limited attention has been paid to the follow-up of hospitalized patients on the basis of clinical setting and the expertise of clinical management.
In the present single-centered, retrospective, observational study, we reported findings from 87 consecutive laboratory-confirmed COVID-19 patients with moderate-to-severe acute respiratory syndrome hospitalized in an intermediate Respiratory Intensive Care Unit (RICU), subdividing the patients in two groups according to the admission date (before and after March 29, 2020).
With improved skills in the clinical management of COVID-19, we observed a significant lower mortality in the T2 group compared with the T1 group and a significantly difference in terms of mortality among the patients transferred in Intensive Care Unit (ICU) from our intermediate RICU (100% in T1 group vs. 33.3% in T2 group). The average length of stay in intermediate RICU of ICU-transferred patients who survived in T1 and T2 was significantly longer than those who died (who died 3.3 ± 2.8 days vs. who survived 6.4 ± 3.3 days).
The present findings suggested that an intermediate level of hospital care may have the potential to modify survival in COVID-19 patients, particularly in the present phase of a more skilled clinical management of the pandemic.
一些研究调查了实验室确诊的严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)患者的流行病学和临床特征,该病毒引起 2019 年冠状病毒病(COVID-19),但对根据临床环境和临床管理专业知识对住院患者进行随访的关注有限。
在本单中心、回顾性、观察性研究中,我们报告了在中间呼吸重症监护病房(RICU)住院的 87 例实验室确诊的 COVID-19 中度至重度急性呼吸综合征患者的发现,根据入院日期(2020 年 3 月 29 日之前和之后)将患者分为两组。
随着 COVID-19 临床管理技能的提高,我们观察到 T2 组的死亡率明显低于 T1 组,并且在从中等 RICU 转入重症监护病房(ICU)的患者中死亡率存在显著差异(T1 组为 100%,T2 组为 33.3%)。在 T1 和 T2 中幸存的从中等 RICU 转入 ICU 的患者的平均住院时间明显长于死亡患者(死亡患者为 3.3±2.8 天,存活患者为 6.4±3.3 天)。
本研究结果表明,中间水平的医院治疗可能有潜力改变 COVID-19 患者的生存,特别是在当前对大流行的临床管理技能更高的阶段。